How to Prevent ASCVD Risk
Promote healthy lifestyle throughout life as the foundation, then use the PREVENT-ASCVD risk calculator for adults 40-75 years to guide statin therapy decisions, targeting LDL-C <100 mg/dL in high-risk individuals and <130 mg/dL in low-risk individuals 1, 2.
Risk Assessment Framework
Start with systematic screening:
- Obtain lipid panel every 5 years after age 19, including at least one lifetime Lp(a) measurement 3
- For adults 40-75 years: Calculate 10-year ASCVD risk using PREVENT-ASCVD equations before starting any pharmacotherapy 1
- For adults 30-59 years: Also calculate 30-year risk to guide long-term prevention strategies 2
- Consider coronary artery calcium scoring in select individuals when treatment decisions remain uncertain 1
Lifestyle Interventions (Universal Foundation)
These apply to ALL adults regardless of risk level 1:
Diet:
- Emphasize vegetables, fruits, nuts, whole grains, lean protein, and fish
- Minimize trans fats, processed meats, refined carbohydrates, and sweetened beverages
- Mediterranean and DASH dietary patterns show strongest evidence for ASCVD risk reduction 4
Physical Activity:
- 150 minutes/week of moderate-intensity activity OR
- 75 minutes/week of vigorous-intensity activity 1
Weight Management:
- Target 5-10% body weight reduction in those with overweight/obesity 5
- Pharmacological weight management for BMI ≥30 kg/m² (or ≥27 kg/m² with ASCVD risk factors) 5
Tobacco:
- Assess at every healthcare visit
- Strongly advise and assist all tobacco users to quit 1
Pharmacological Prevention by Risk Category
Blood Pressure Management
Target <130/80 mmHg (consider <120 mmHg systolic in high-risk individuals) 1, 5
- Start with nonpharmacological interventions for all
- Add antihypertensive therapy when targets not met with lifestyle alone
Lipid Management (Statin Therapy First-Line)
Automatic statin indications 1, 2:
- LDL-C ≥190 mg/dL: High-intensity statin
- Diabetes mellitus ages 40-75: Moderate-to-high intensity statin
- 10-year ASCVD risk determined sufficient after clinician-patient discussion
- High-risk individuals: <100 mg/dL
- Moderate-risk individuals: <115 mg/dL
- Low-risk individuals: <130 mg/dL
Combination therapy when statin alone insufficient 2:
- Add ezetimibe as second-line
- Add PCSK9 monoclonal antibody for additional LDL-C lowering
- Add bempedoic acid as alternative option
Diabetes Management
For type 2 diabetes 1:
- Lifestyle changes are crucial foundation
- Metformin first-line pharmacotherapy
- Consider SGLT2 inhibitor or GLP-1 receptor agonist as second-line (these have proven ASCVD prevention benefits) 5
- Target HbA1c <7.0% 5
Aspirin
Use infrequently in routine primary prevention due to lack of net benefit 1. The bleeding risk typically outweighs ASCVD prevention benefit in primary prevention populations.
Special Populations
Young adults with diabetes (<30 years) 2:
- Consider moderate-intensity statin if type 2 diabetes ≥10 years OR type 1 diabetes ≥20 years
- Consider if ≥1 major CVD risk factors present (retinopathy, neuropathy, nephropathy, ankle-brachial index <0.9)
Chronic kidney disease with diabetes 5:
- ACE inhibitor, GLP-1 receptor agonist, SGLT2 inhibitor, or finerenone for ASCVD prevention
Implementation Strategy
Use team-based care approach 1:
- Evaluate social determinants of health affecting treatment decisions
- Engage multidisciplinary teams for comprehensive risk reduction
- Address health literacy for both patients and providers 6
Critical pitfall to avoid: The cumulative lifetime exposure to elevated atherogenic lipoproteins drives ASCVD risk 2, 6. Don't delay intervention in younger adults with significantly elevated risk factors—calculate 30-year risk and consider earlier intervention rather than waiting until 10-year risk becomes high.
Monitor and adjust: Reassess lipid levels, blood pressure, and diabetes control regularly to ensure treatment targets are met. Adherence to therapy is essential for long-term benefit 6.